CN112041301A - 具有铁死亡诱导活性的化合物及其使用方法 - Google Patents

具有铁死亡诱导活性的化合物及其使用方法 Download PDF

Info

Publication number
CN112041301A
CN112041301A CN201980028824.0A CN201980028824A CN112041301A CN 112041301 A CN112041301 A CN 112041301A CN 201980028824 A CN201980028824 A CN 201980028824A CN 112041301 A CN112041301 A CN 112041301A
Authority
CN
China
Prior art keywords
alkyl
alkenyl
heterocyclyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980028824.0A
Other languages
English (en)
Chinese (zh)
Inventor
蒋春
陈瑞红
A·潘迪
B·卡里塔
A·J·杜赖斯瓦米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferro Therapeutics Inc
Original Assignee
Ferro Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferro Therapeutics Inc filed Critical Ferro Therapeutics Inc
Publication of CN112041301A publication Critical patent/CN112041301A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201980028824.0A 2018-02-28 2019-02-27 具有铁死亡诱导活性的化合物及其使用方法 Pending CN112041301A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636614P 2018-02-28 2018-02-28
US62/636,614 2018-02-28
PCT/US2019/019854 WO2019168999A1 (en) 2018-02-28 2019-02-27 Compounds with ferroptosis inducing activity and methods of their use

Publications (1)

Publication Number Publication Date
CN112041301A true CN112041301A (zh) 2020-12-04

Family

ID=65729467

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980028824.0A Pending CN112041301A (zh) 2018-02-28 2019-02-27 具有铁死亡诱导活性的化合物及其使用方法

Country Status (16)

Country Link
US (2) US11098040B2 (enExample)
EP (1) EP3759075B1 (enExample)
JP (1) JP7348906B2 (enExample)
KR (1) KR20200135961A (enExample)
CN (1) CN112041301A (enExample)
AR (2) AR114417A1 (enExample)
AU (1) AU2019229256A1 (enExample)
BR (1) BR112020017561A2 (enExample)
CA (1) CA3092143A1 (enExample)
EA (1) EA202091846A1 (enExample)
ES (1) ES3038012T3 (enExample)
IL (1) IL276788A (enExample)
MX (2) MX2020008906A (enExample)
SG (1) SG11202008230PA (enExample)
TW (1) TW202000663A (enExample)
WO (1) WO2019168999A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113336748A (zh) * 2021-04-12 2021-09-03 北京大学 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物
CN114008024A (zh) * 2019-02-27 2022-02-01 费罗治疗公司 具有铁死亡诱导活性的化合物以及使用其的方法
CN118994147A (zh) * 2024-07-18 2024-11-22 中国海洋大学 一种基于疏水标签的gpx4蛋白降解剂及其制备方法和应用
CN120923499A (zh) * 2025-08-08 2025-11-11 兰州大学 一种铁死亡激动剂、缺氧响应型纳米共递送系统及其应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
WO2021041539A2 (en) * 2019-08-28 2021-03-04 Ferro Therapeutics, Inc. Compounds and methods of use
CN110511253B (zh) * 2019-09-04 2023-10-13 上海药明康德新药开发有限公司 DNA编码化合物库构建中On-DNA四氢-β-咔啉类化合物的合成方法
CN110627786B (zh) * 2019-10-29 2020-11-24 株洲千金药业股份有限公司 一种他达拉非中间体的制备方法
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US11998534B2 (en) * 2020-02-12 2024-06-04 Eubulus Biotherapeutics Inc. GPX4 inhibitor in combination with anticancer agent for treating proliferative disease
JP2023518132A (ja) * 2020-03-06 2023-04-27 ベイジン・シノタウ・バイオ－ファーマシューティカルズ・テクノロジー・カンパニー，リミテッド Ｃｔｂ００６とポナチニブとの併用の適用
TW202227399A (zh) * 2020-08-26 2022-07-16 美商費洛醫療公司 化合物及使用方法
KR20230128471A (ko) * 2020-12-04 2023-09-05 에우불루스 바이오테라퓨틱스 인코포레이티드 헤테로아릴-아세틸렌, 이의 약제학적 조성물, 및 이의치료적 적용
WO2022216066A1 (ko) * 2021-04-08 2022-10-13 서울대학교산학협력단 암 환자의 예후 예측용 바이오마커 및 이의 용도
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
WO2024015637A1 (en) * 2022-07-15 2024-01-18 Ferro Therapeutics, Inc. Glutathione peroxidase 4 (gpx4) inhibitors for the treatment of cancer
AU2023324856A1 (en) * 2022-08-19 2025-01-30 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
WO2024123412A1 (en) * 2022-12-09 2024-06-13 The University Of Toledo Ferroptosis inducers to treat cancer

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1195349A (zh) * 1995-07-14 1998-10-07 艾科斯有限公司 环磷酸鸟苷特异性磷酸二酯酶抑制剂
WO2001094347A1 (en) * 2000-06-08 2001-12-13 Lilly Icos Llc Tetracyclic diketopiperazine compounds as pdev inhibitors
WO2002028858A2 (en) * 2000-10-02 2002-04-11 Lilly Icos Llc Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
US20030225092A1 (en) * 2000-06-07 2003-12-04 Orme Mark W. Chemical compounds
WO2007016361A2 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
FR2916200A1 (fr) * 2007-05-18 2008-11-21 Fourtillan Snc Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
WO2017120445A1 (en) * 2016-01-07 2017-07-13 The Broad Institute, Inc. Compounds and methods for increasing tumor infiltration by immune cells

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03004023A (es) 2000-11-08 2004-02-12 Lilly Icos Llc Compuestos quimicos.
EP1914235A1 (en) 2006-10-10 2008-04-23 Universite de Lille 2 Droit et Santé Chiral tetra-hydro beta-carboline derivatives and applications thereof as antiparasitic compounds
WO2008103470A2 (en) 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
US9169247B2 (en) 2009-11-20 2015-10-27 Southern Research Institute Tetrahydro-beta-carboline derivatives, synthesis and use thereof
US9695133B2 (en) * 2012-07-13 2017-07-04 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
WO2015051149A1 (en) 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Sorafenib analogs and uses thereof
EP3094332B1 (en) 2014-01-15 2018-09-12 The Trustees of Columbia University in the City of New York Carbonyl erastin analogs and their use
US20170342021A1 (en) 2014-12-16 2017-11-30 Adt Pharmaceuticals, Inc. Ras-inhibiting indenyl acetamide compounds, compositions, and uses
US10736972B2 (en) 2015-05-29 2020-08-11 Memorial Sloan Kettering Cancer Center Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
JP6592197B2 (ja) 2015-11-12 2019-10-16 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． アクリル酸誘導体、製造方法、および医薬としてのその使用
BR112018013730B1 (pt) 2016-01-08 2022-06-28 Championx Usa Inc. Método para intensificar a produção e/ou o transporte de óleo bruto
KR102479822B1 (ko) 2016-02-05 2022-12-21 인벤티스바이오 엘엘씨 선택적 에스트로겐 수용체 분해제 및 이들의 용도
WO2018118711A1 (en) 2016-12-19 2018-06-28 The Trustees Of Columbia University In The City Of New York Small molecule ferroptosis inducers
EP3630089A4 (en) 2017-05-24 2021-06-09 Ferro Therapeutics, Inc. PROCEDURE FOR CANCER THERAPY
US11530413B2 (en) 2017-07-21 2022-12-20 Novartis Ag Compositions and methods to treat cancer
WO2019106434A1 (en) 2017-12-01 2019-06-06 Collaborative Medicinal Development Pty. Ltd. Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders
US20200383943A1 (en) 2017-12-04 2020-12-10 Memorial Sloan Kettering Cancer Center Methods of cancer treatment via regulated ferroptosis
CN109796424A (zh) 2019-02-19 2019-05-24 四川大学 一种抑制铁死亡的小分子化合物及其制备方法与应用
TW202045480A (zh) 2019-02-27 2020-12-16 美商費洛醫療公司 化合物及使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1195349A (zh) * 1995-07-14 1998-10-07 艾科斯有限公司 环磷酸鸟苷特异性磷酸二酯酶抑制剂
US20030225092A1 (en) * 2000-06-07 2003-12-04 Orme Mark W. Chemical compounds
WO2001094347A1 (en) * 2000-06-08 2001-12-13 Lilly Icos Llc Tetracyclic diketopiperazine compounds as pdev inhibitors
WO2002028858A2 (en) * 2000-10-02 2002-04-11 Lilly Icos Llc Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
WO2007016361A2 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
FR2916200A1 (fr) * 2007-05-18 2008-11-21 Fourtillan Snc Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
WO2017120445A1 (en) * 2016-01-07 2017-07-13 The Broad Institute, Inc. Compounds and methods for increasing tumor infiltration by immune cells

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114008024A (zh) * 2019-02-27 2022-02-01 费罗治疗公司 具有铁死亡诱导活性的化合物以及使用其的方法
CN113336748A (zh) * 2021-04-12 2021-09-03 北京大学 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物
CN113336748B (zh) * 2021-04-12 2022-03-25 北京大学 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物
CN118994147A (zh) * 2024-07-18 2024-11-22 中国海洋大学 一种基于疏水标签的gpx4蛋白降解剂及其制备方法和应用
CN120923499A (zh) * 2025-08-08 2025-11-11 兰州大学 一种铁死亡激动剂、缺氧响应型纳米共递送系统及其应用

Also Published As

Publication number Publication date
CA3092143A1 (en) 2019-09-06
TW202000663A (zh) 2020-01-01
MX2020008906A (es) 2021-02-26
US20230039846A1 (en) 2023-02-09
EP3759075B1 (en) 2025-07-23
US11098040B2 (en) 2021-08-24
MX2023001527A (es) 2023-03-06
ES3038012T3 (en) 2025-10-08
KR20200135961A (ko) 2020-12-04
AR118205A1 (es) 2021-09-22
IL276788A (en) 2020-10-29
US20190263802A1 (en) 2019-08-29
EA202091846A1 (ru) 2021-06-01
EP3759075A1 (en) 2021-01-06
JP7348906B2 (ja) 2023-09-21
JP2021515010A (ja) 2021-06-17
WO2019168999A1 (en) 2019-09-06
BR112020017561A2 (pt) 2020-12-22
AR114417A1 (es) 2020-09-02
AU2019229256A1 (en) 2020-09-17
SG11202008230PA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
CN112041301A (zh) 具有铁死亡诱导活性的化合物及其使用方法
KR102533599B1 (ko) 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
JP7367169B2 (ja) Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
RU2730506C2 (ru) Твердые формы соединения, модулирующего киназы
JP7379467B2 (ja) Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
CN114867735A (zh) Ras抑制剂
CN114008024A (zh) 具有铁死亡诱导活性的化合物以及使用其的方法
CN112955438A (zh) 蛋白质酪氨酸磷酸酶抑制剂和其使用方法
AU2024323620A1 (en) Crystalline forms of a pi3k inhibitor and uses of same
US11040964B2 (en) Compounds and methods of use
JP2020507566A (ja) ベンゾチオフェンエストロゲン受容体モジュレーター
CN116348455A (zh) 蛋白质酪氨酸磷酸酶抑制剂和其使用方法
AU2019239952A1 (en) Compounds and methods for IDO and TDO modulation, and indications therefor
US20250032623A1 (en) Heterobifunctional compounds and their use in treating disease
WO2018186366A1 (ja) 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
CN117693517A (zh) 用于靶向治疗肾癌的新型化合物和组合物
HK40067758A (en) Compounds with ferroptosis inducing activity and methods of their use
WO2016111957A1 (en) Chloroquinoline triazole compounds, composition and uses
HK40097088A (zh) 作为ras抑制剂以治疗癌症的吲哚衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201204

WD01 Invention patent application deemed withdrawn after publication